Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Josep M Llibre

Showing results (51-60 of 162) with videos related to

Pageof 17
Sort By:
AIDS (London, England)|June 17, 2004
Improvement of dyslipidemia in patients switching from stavudine to tenofovir: preliminary resultsPere Domingo, Pablo Labarga, Rosario Palacios, et al.
HIV Clinical Trials|February 6, 2010
Efficacy and safety of switching from enfuvirtide to raltegravir in patients with virological suppressionJosé R Santos, Josep M Llibre, Elena Ferrer, et al.
AIDS (London, England)|June 23, 2006
Sustained improvement of dyslipidaemia in HAART-treated patients replacing stavudine with tenofovirJosep M Llibre, Pere Domingo, Rosario Palacios, et al.
Antiviral Therapy|January 25, 2014
Effectiveness of efavirenz compared with ritonavir-boosted protease-inhibitor-based regimens as initial therapy for patients with plasma HIV-1 RNA above 100,000 copies/mlArkaitz Imaz, Josep M Llibre, Jordi Navarro, et al.
The Journal of Antimicrobial Chemotherapy|February 13, 2026
Closing the PrEP access gap in Europe: a strategic framework for equity and innovation among difficult-to-reach populationsJosep M Llibre, Carlos Iniesta, Victoria Tittle, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 13, 2022
Brief Report: Evaluation of Inflammation and Atherogenesis Biomarkers Through 148 Weeks Postswitch to Dolutegravir and Rilpivirine in SWORD-1/SWORD-2Josep M Llibre, Luis Fernando López Cortés, Alicia Aylott, et al.
The Journal of Antimicrobial Chemotherapy|December 20, 2014
Monotherapy with boosted PIs as an ART simplification strategy in clinical practiceJosé R Santos, Josep M Llibre, Daniel Berrio-Galan, et al.
Enfermedades Infecciosas Y Microbiologia Clinica (English Ed.)|September 6, 2016
Cost-effectiveness of initial antiretroviral treatment administered as single vs. multiple tablet regimens with the same or different componentsJosep M Llibre, Elisa de Lazzari, Jean-Michel Molina, et al.
AIDS (London, England)|July 31, 2012
Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapiesLourdes Anta, Josep M Llibre, Eva Poveda, et al.
AIDS (London, England)|May 15, 2010
Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL studyEsteban Martínez, María Larrousse, Josep M Llibre, et al.
Pageof 17

Showing results (51-60 of 162) with videos related to

Sort By:
Pageof 17
AIDS (London, England)|June 17, 2004
Improvement of dyslipidemia in patients switching from stavudine to tenofovir: preliminary resultsPere Domingo, Pablo Labarga, Rosario Palacios, et al.
HIV Clinical Trials|February 6, 2010
Efficacy and safety of switching from enfuvirtide to raltegravir in patients with virological suppressionJosé R Santos, Josep M Llibre, Elena Ferrer, et al.
AIDS (London, England)|June 23, 2006
Sustained improvement of dyslipidaemia in HAART-treated patients replacing stavudine with tenofovirJosep M Llibre, Pere Domingo, Rosario Palacios, et al.
Antiviral Therapy|January 25, 2014
Effectiveness of efavirenz compared with ritonavir-boosted protease-inhibitor-based regimens as initial therapy for patients with plasma HIV-1 RNA above 100,000 copies/mlArkaitz Imaz, Josep M Llibre, Jordi Navarro, et al.
The Journal of Antimicrobial Chemotherapy|February 13, 2026
Closing the PrEP access gap in Europe: a strategic framework for equity and innovation among difficult-to-reach populationsJosep M Llibre, Carlos Iniesta, Victoria Tittle, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 13, 2022
Brief Report: Evaluation of Inflammation and Atherogenesis Biomarkers Through 148 Weeks Postswitch to Dolutegravir and Rilpivirine in SWORD-1/SWORD-2Josep M Llibre, Luis Fernando López Cortés, Alicia Aylott, et al.
The Journal of Antimicrobial Chemotherapy|December 20, 2014
Monotherapy with boosted PIs as an ART simplification strategy in clinical practiceJosé R Santos, Josep M Llibre, Daniel Berrio-Galan, et al.
Enfermedades Infecciosas Y Microbiologia Clinica (English Ed.)|September 6, 2016
Cost-effectiveness of initial antiretroviral treatment administered as single vs. multiple tablet regimens with the same or different componentsJosep M Llibre, Elisa de Lazzari, Jean-Michel Molina, et al.
AIDS (London, England)|July 31, 2012
Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapiesLourdes Anta, Josep M Llibre, Eva Poveda, et al.
AIDS (London, England)|May 15, 2010
Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL studyEsteban Martínez, María Larrousse, Josep M Llibre, et al.
Pageof 17